Apollomics, Inc. (NASDAQ:APLMW) Sees Large Drop in Short Interest

Apollomics, Inc. (NASDAQ:APLMW) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 68,200 shares, a decline of 55.0% from the November 30th total of 151,500 shares. Based on an average daily volume of 79,400 shares, the short-interest ratio is presently 0.9 days.

Apollomics Price Performance

NASDAQ:APLMW opened at $0.01 on Friday. The company’s 50 day moving average is $0.01 and its 200-day moving average is $0.01. Apollomics has a 12 month low of $0.01 and a 12 month high of $0.04.

About Apollomics

Apollomics, Inc, a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways.